Can a simple inhaler shield lung cancer patients from radiation side effects?

NCT ID NCT03803787

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether taking inhaled budesonide (a steroid) twice daily during radiation therapy can reduce the severity of radiation pneumonitis—a common and serious lung inflammation—in people with non-small cell lung cancer. About 72 patients will be randomly assigned to receive the inhaler or not. The goal is to see if the steroid lowers the grade of pneumonitis and whether it affects the cancer treatment's success.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Inhaled budesonide (a steroid)
What this could lead to
If it works, this could offer a simple way to prevent or lessen lung inflammation caused by radiation therapy in lung cancer patients.
What could go wrong
This is a small, early-phase trial with only 72 participants, so results may not apply broadly. The steroid may not reduce pneumonitis or could affect the cancer treatment's effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RADIATION PNEUMONITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Instituto Nacional de Cancerologia

    RECRUITING

    Mexico City, 14080, Mexico

    Contact Email: •••••@•••••

  • Instituto Nacional de Enfermedades Respiratorias

    ACTIVE_NOT_RECRUITING

    Mexico City, 14080, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.